Maintenance Therapy Using Lenalidomide in Myeloma
Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).
Sponsor: Celgene
This PHASE3 trial investigates Myeloma and is currently completed. Celgene leads this study, which shows 9 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
May 2019 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Mar 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jun 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
- Intergroupe Francophone du Myelome
- University Hospital, Toulouse
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarau, Switzerland, Aix-en-Provence, France, Amiens, France, Angers, France, Antwerp, Belgium, Argenteuil, France, Arlon, Belgium, Avignon, France, Basel, Switzerland, Bayonne, France and 53 more location s